Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01492907 · ClinicalTrials.gov registry record · Phase 1

Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer

A Phase 1 study of Pancreatic Cancer, sponsored by University of Minnesota.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT01492907: Completed Phase 1 study of Pancreatic Cancer, sponsored by University of Minnesota.

NCT01492907 is a Phase 1 study of Pancreatic Cancer that has completed, run by University of Minnesota. The registered enrollment target is 8 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01492907, a Phase 1 study of Pancreatic Cancer, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Study Design: This is a single institution pilot study to recruit 4 patients with operable pancreatic cancer scheduled for a pancreatectomy and 4 age/sex matched normal controls. Both groups will receive a single oral dose of radiolabeled MelQx followed by serial blood draws over an 8 hour period and urine collections over a 24 hour period. In addition, normal pancreatic tissue and normal small bowel tissue will be collected by Tissue Procurement from resected (waste) tissue at the time of pancreatectomy on the 4 pancreatic cancer patients.

Primary Outcome

Metabolite levels will be expressed as the percent of total recovered radioactivity in plasma. Metabolite profiles will be qualitatively compared between cases and controls, which will include the mean, median, standard deviation, range and 90% confidence interval for the major detoxification metabolites.

Conditions Studied

Pancreatic Cancer

Interventions

  • PROCEDURE Pancreatectomy
  • RADIATION MeIQx

Study Locations (1)

Minnesota

  • Masonic Cancer Center, University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2012-01
Est. Completion 2013-04
Phase Phase 1
University of Minnesota

966 total trials

What the finished NCT01492907 record still lists

NCT01492907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pancreatectomy is the first listed.

NCT01492907 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT01492907 about?

NCT01492907 is a clinical study titled "Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer". Study Design: This is a single institution pilot study to recruit 4 patients with operable pancreatic cancer scheduled for a pancreatectomy and 4 age/sex matched normal controls. Both groups will receive a single oral dose of radiolabeled MelQx followed by serial blood draws over an 8 hour period a...

What is the current status of trial NCT01492907?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2012-01. Estimated completion is 2013-04.

What conditions does trial NCT01492907 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT01492907?

The interventions under investigation include: Pancreatectomy (PROCEDURE), MeIQx (RADIATION).

Who is sponsoring clinical trial NCT01492907?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01492907 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01492907's enrollment target sits among peer trials

8 270th of 278 higher than 8 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01492907, the US trial registry maintained by the National Library of Medicine. NCT01492907 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.